Diseases & Conditions
Grants & Contracts
News & Events
NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.
The ACTG NL consists of Core Laboratory groups in immunology, pharmacology, virology and TB.
The Tufts New England Regional Biosafety Laboratory (RBL) is one of the NIAID-supported Regional Biocontainment Laboratories.
The drug screening team at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) can test and characterize the antiviral activity of novel compounds, drugs, and antibodies against multiple viruses in multiple cell lines under a variety of conditions.
This service can be used to develop and perform a variety of analytical assays to assess the properties of drug substances and their formulations.
This service provides follow-up studies of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.
This service can be used to provide pharmacokinetic and safety assessments of products in mice, rats, rabbits, dogs, and nonhuman primates.
The ImmuneSpace database is currently composed of 21 studies covering 10 types of assays and 2,500 total participants.
The immunology laboratory at the Integrated Research Facility at Fort Detrick (IRF-Frederick) offers a variety of capabilities to interrogate the immune responses against pathogens requiring maximum containment.
The main purpose of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Laboratory Center is to support the network’s scientific agenda by providing state of the art laboratory testing in support of clinical trials, new works concept sheets (NWCS), and data analysis con
The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical speci
The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins.
Note: Devices are excluded.
The National Swine Resource and Research Center (NSRRC) was established in 2003 to develop the infrastructure to ensure that biomedical investigators across a variety of disciplines have access to critically needed swine models of human health and disease.
The Nonhuman Primate Reagent Resource is funded by the National Institutes of Health to facilitate the optimal use of nonhuman primate models in biomedical research.
The primary objective of the response team is to develop and foster overseas relationships through the support of research studies and clinical trials.
The Chemical Countermeasures Research Program (CCRP) supports the discovery and early development of medical countermeasures (MCMs) to treat the acute and/or long-term chronic toxicities after exposure to highly tox
The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.
The Vaccine Development Services program offers a collection of preclinical services to support the development of vaccines intended for use in the investigation, control, prevention, and treatment of a wide range of infectious agents (other than HIV).
The virology team at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) has extensive expertise working with a range of high‑consequence viral pathogens.